Photopheresis plus mogamulizumab for advanced skin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign the consent form (or a legal representative can).
- Your skin lymphoma diagnosis (mycosis fungoides or Sézary syndrome) must be confirmed by pathology, and your disease stage must meet the trial’s stage rules.
- You must have measurable disease in the skin and/or blood (using the trial’s skin/blood scoring/counts).
- Recent test results must meet minimum blood, liver, kidney, and clotting levels within set time windows.
- You must be able to provide a skin biopsy sample taken within the last 6 months for central expert review.
- You must not have had certain prior treatments recently, and you cannot have prior mogamulizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study looks at a common skin rash caused by the drug mogamulizumab in patients with certain types of lymphoma. It aims to learn more about the rash and how to manage it, so your experience can help future patients.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This trial tests whether a special light treatment done outside the body (extracorporeal photopheresis) can help people with Sezary syndrome. It is meant to see if the treatment is safe and effective for this specific type and stage of skin lymphoma.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Hear when a new Primary Cutaneous T-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.